Management of IBD Sprint or Marathon Challenges and Unmet Needs The Sprint When Sprinting Matters After the Sprint What Happens Next The Marathon LongTerm Remission Why Is It Important Colectomy Rates in Patients With UC Are Decreasing ID: 736622
Download Presentation The PPT/PDF document "Managing IBD Treatment of IBD" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Managing IBDSlide2
Treatment of IBDSlide3
Management of IBD
Sprint or Marathon?Slide4
Challenges and Unmet NeedsSlide5
The SprintSlide6
When Sprinting MattersSlide7
After the Sprint
What Happens Next?Slide8
The MarathonSlide9
Long-Term Remission
Why Is It Important?Slide10
Colectomy Rates in Patients With UC Are Decreasing
Swiss IBD Cohort StudySlide11
Long-Term Remission
Why Is It Important (cont)?Slide12
Steroids for the Treatment of CD
Benefit for the PatientSlide13
Steroids for the Treatment of UC
Symptomatic ControlSlide14
Thiopurines Prevent the Need for Surgery
in CDSlide15
Mucosal Healing as a Treatment GoalSlide16
Step Up, Top Down
Early Aggressive Therapy Causes Mucosal Healing in CDSlide17
Achievement of Mucosal Healing With Immunomodulators and Biological TherapySlide18
Benefits of Biological Agents for CDSlide19
Over Half of Patients Have a Primary or Secondary Loss of Response to Anti-TNF TherapiesSlide20
Lasting Clinical Remission With Vedolizumab
5-Year Cumulative Exposure DataSlide21
Sustained Clinical Remission Rates With Ustekinumab (2-Year Data)Slide22
Immunogenicity of Newer TherapiesSlide23
Best Practice for Managing the
Sprint vs MarathonSlide24
Treatment Options
Choosing a Biological Therapy for the MarathonSlide25
Evidence Beyond Clinical Trials on the Use of Vedolizumab and UstekinumabSlide26
VICTORY Consortium
Vedolizumab vs Anti-TNF Therapy (Propensity Score-Matched Analysis)Slide27
Key Considerations When Selecting a Therapy for an Individual PatientSlide28
Treatment PersistencySlide29
Targeting the Right Drug to the Individual Patient at the Right TimeSlide30
Monitoring Patients
Beyond Clinical SymptomsSlide31
Effective Infection Management May Improve Treatment PersistencySlide32
Concluding RemarksSlide33